Latest Breaking News On - Hungarian national institute - Page 3 : comparemela.com

Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination TIANJIN, China, April 8, 2021 /PRNewswire/ CanSino Biologics Inc. ( CanSinoBIO ) (HKEX: 06185) today announced that the Instituto de Salud Pública de Chile ( ISP ) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™). This marks the first approval of Convidecia™ in South America and the first single-dose COVID-19 vaccine approved for emergency use in Chile. On February 25, 2021, Convidecia™ was granted a conditional marketing authorization by the National Medical Products Administration of China ( NMPA ), the first of its kind authorized in China. Globally, Convidecia™ received authorization for emergency use by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI) in Ma

United statesPrnewswire cansino biologics incCommission for protectionDrug regulatory authority of pakistanNational medical products administration of chinaHungarian national institute of pharmacySouth americaSino biologicsRecombinant novel coronavirus vaccineAdenovirus typeNational medical products administrationHungarian national instituteFederal commissionSanitary risksDrug regulatory authorityஒன்றுபட்டது மாநிலங்களில்